Akebia Therapeutics is a technology company.
Akebia Therapeutics has raised $88.0M across 3 funding rounds.
Akebia Therapeutics has raised $88.0M in total across 3 funding rounds.
Akebia Therapeutics has raised $88.0M in total across 3 funding rounds.
Akebia Therapeutics's investors include Cincy Tech, Frazier Healthcare Partners, Vivo Capital.
Akebia Therapeutics is a biopharmaceutical company, not a general technology company, specializing in therapies for kidney disease. Founded in 2007 and headquartered in Cambridge, Massachusetts, it develops and commercializes innovative treatments targeting unmet needs in renal care, particularly anemia associated with chronic kidney disease (CKD).[1][2][3][4] The company serves patients with kidney disease, nephrologists, dialysis centers, and the broader renal community through two FDA-approved products and a late-stage pipeline candidate like vadadustat, an oral therapy leveraging hypoxia-inducible factor (HIF) biology to address anemia in both dialysis and non-dialysis CKD patients.[2][3][4] Its growth momentum stems from a fully integrated model with commercial teams, global partnerships, and ongoing Phase 3 trials (PRO2TECT and INNO2VATE), positioning it as a leader in the renal space.[1][2][4]
Akebia Therapeutics was founded in 2007 in the biotech hub of Kendall Square, Cambridge, Massachusetts, with a focus on discovering novel therapeutics based on HIF biology—a key regulator in oxygen sensing and multiple biological pathways relevant to kidney disease.[2][3][4] The idea emerged from scientific insights into hypoxia's role in renal disorders, aiming to develop solutions for complications like anemia in CKD patients.[1][4] Early traction came from advancing HIF-based candidates, culminating in FDA approvals for products and a 2018 merger with Keryx Biopharmaceuticals, which bolstered its commercial capabilities in nephrology.[2] Leadership, including CEO John Butler with expertise in renal and metabolic drugs, has driven evolution from R&D-focused startup to a fully integrated biopharma with global partners.[2]
Akebia rides the wave of precision medicine in nephrology, where aging populations and rising CKD prevalence (affecting millions globally) demand oral, convenient alternatives to injectable erythropoiesis-stimulating agents (ESAs).[1][4] Timing aligns with advances in HIF science and post-merger scale, enabling competition in a market dominated by incumbents amid regulatory shifts favoring anemia innovation.[2][4] Favorable forces include biotech hub synergies in Massachusetts, partnerships accelerating global trials, and emphasis on unmet renal needs, influencing the ecosystem by setting new care standards and expanding oral therapy adoption.[2][3][4]
Akebia's trajectory hinges on vadadustat's potential approvals and commercialization, alongside pipeline expansion in kidney care.[1][3] Trends like personalized renal therapies, AI-driven drug discovery, and value-based care will shape growth, potentially amplifying its renal leadership if Phase 3 data succeeds.[4] Influence may evolve through acquisitions or alliances, solidifying its role beyond anemia to broader CKD solutions—transforming lives as its kidney-focused mission promises.[1][2] This positions Akebia as a biopharma innovator improving patient outcomes in a high-need field.
Akebia Therapeutics has raised $88.0M across 3 funding rounds. Most recently, it raised $41.0M Series C in June 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2013 | $41.0M Series C | Cincy Tech, Frazier Healthcare Partners, Vivo Capital | |
| Apr 1, 2011 | $22.0M Series B | Cincy Tech | |
| Jul 1, 2009 | $25.0M Series A | Cincy Tech |